

Increase in the resources allocated to the liquidity contract entrusted to Invest Securities

Paris, July 31, 2023 – 7:30 AM CEST – Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique: ALIKO), announces today that it has increased by 10,000 Euros (ten thousand euros), the resources allocated to its liquidity agreement with INVEST SECURITIES.

This increase complies with the decision of the French Financial Market Authority (Autorité des marchés financiers or AMF) N° 2021-01 of 22nd June 2021 establishing liquidity agreements on equity securities as an accepted market practice (the » AMF decision »)

On July 28 2023 after this increase in the amount of cash allocated to the liquidity contract, the available resources are as follows:

- 51,908 shares
- 10,250.54 €

For the record, as of the half year statement on 30/06/2023 the following assets appeared on the liquidity account:

- 43,011 shares
- 14,540.09 €

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to www.ikonisys.com

Contacts

Ikonisys

Alessandro Mauri
CFO
investors@ikonisys.com

NewCap

Louis-Victor Delouvrier
Investor Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 92

NewCap

Nicolas Merigeau
Media Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98